Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice.
Open Access
- 1 October 1993
- Vol. 48 (10) , 959-966
- https://doi.org/10.1136/thx.48.10.959
Abstract
BACKGROUND--Increased production of transforming growth factor beta (TGF-beta) seems to have an important role in the pathophysiology of bleomycin induced lung fibrosis. This is attributed to the ability of TGF-beta to stimulate infiltration of inflammatory cells and promote synthesis of connective tissue, leading to collagen deposition. METHODS--The study was designed to evaluate the antifibrotic potential of TGF-beta antibody in mice treated with bleomycin, which is a model of lung fibrosis. Under methoxyflurane anaesthesia, each mouse received intratracheally either 50 microliters sterile isotonic saline or 0.125 units bleomycin in 50 microliters. Within five minutes after the instillation, mice received into the tail vein 100 microliters non-immune rabbit IgG, TGF-beta 2 antibody, or a combination of TGF-beta 2 and TGF-beta 1 antibodies at various dose regimens. Mice were killed 14 days after the instillation and their lungs processed for morphological and biochemical studies. RESULTS--Administration of 250 micrograms of TGF-beta 2 antibody after instillation of bleomycin followed by 100 micrograms on day 5 and 100 micrograms on day 9 significantly reduced the bleomycin induced increases in the accumulation of lung collagen from 445.8 (42.3) micrograms/lung to 336.7 (56.6) micrograms/lung at 14 days. Similarly, the combined treatment with 250 micrograms TGF-beta 2 antibody and 250 micrograms TGF-beta 1 antibody after bleomycin instillation followed by 100 micrograms of each antibody on day 5 also caused a significant reduction in bleomycin induced increases in lung collagen accumulation and myeloperoxidase activity at 14 days. CONCLUSIONS--These results suggest that TGF-beta has an important role in the aetiology of bleomycin induced lung fibrosis; the neutralisation of TGF-beta by systemic treatment with its antibodies offers a new mode of pharmacological intervention which may be useful in treating lung fibrosis.Keywords
This publication has 38 references indexed in Scilit:
- Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosisNature, 1990
- Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation.The Journal of Experimental Medicine, 1989
- Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.The Journal of Experimental Medicine, 1989
- Tissue Destruction by NeutrophilsNew England Journal of Medicine, 1989
- Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat.Proceedings of the National Academy of Sciences, 1988
- Transforming Growth Factor-β: Biological Function and Chemical StructureScience, 1986
- Analysis of Bronchoalveolar Lavage Fluid from Bleomycin-Induced Pulmonary Fibrosis in HamstersToxicologic Pathology, 1986
- Effects of intratracheal administration of bleomycin on GSH-shuttle enzymes, catalase, lipid peroxidation, and collagen content in the lungs of hamstersToxicology and Applied Pharmacology, 1983
- Differential distribution of distinct forms of myeloperoxidase in different azurophilic granule subpopulations from human neutrophilsBiochemical and Biophysical Research Communications, 1983
- Pulmonary toxicity of bleomycin analogsToxicology and Applied Pharmacology, 1980